Most adults have never had their Lp(a) measured. Most do not know the test exists, let alone what it measures and who needs it. Their cholesterol panel came back fine and their physician was satisfied. The one number that could have flagged an inherited cardiovascular risk sat unmeasured the entire time. If a parent or sibling had a heart attack early or you want every modifiable risk on the table before deciding what to do about it, this is the test worth knowing about.
Lp(a) or lipoprotein(a), is an inherited lipoprotein particle that is an independent, causal risk factor for heart attack, stroke and aortic stenosis and it is set almost entirely by your genes. It responds to neither diet nor exercise the way ordinary cholesterol does. It is measured once, it changes your risk profile for life and roughly one in five people carries an elevated level. That combination of common, invisible and consequential is why cardiologists keep asking for it and why standard panels keep leaving it out.
- Lp(a) is a genetically determined lipoprotein and an independent, causal risk factor for atherosclerotic disease and aortic stenosis.
- It is measured once in a lifetime because the value is stable by nature and it cannot be lowered meaningfully by diet, exercise or currently approved drugs.
- A high result does not produce a treatment for itself. It raises the stakes on everything you can control, starting with ApoB.
- Lp(a) is included in our quarterly Biomarker Audit inside the $299 per month Cardiometabolic Optimization Membership.
What the particle actually is
An Lp(a) particle is built like an LDL particle, carrying cholesterol and one molecule of ApoB, with one addition: a large protein called apolipoprotein(a) is bolted onto it. That protein is what makes the particle unusual. It resembles a clotting protein, which is one reason high Lp(a) promotes both plaque formation and a clot-friendlier environment. The 2022 American Heart Association scientific statement describes Lp(a) as a genetically determined, causal, common risk factor and those three words are chosen carefully. Genetically determined means you did not cause it. Causal means it does damage rather than merely accompanying it. Common means a meaningful share of the population carries elevated levels without knowing it.
The European Atherosclerosis Society consensus statement reaches the same conclusion and goes further, recommending that Lp(a) be measured at least once in every adult. You can read that position here.
Why once is enough
Most lab values move. Cholesterol responds to the last three months of eating. HbA1c tracks your blood sugar across a season. Weight follows behavior. Lp(a) does none of that. Your level is written into your DNA at the LPA gene, it is largely established in childhood and it varies by less than about ten percent across a lifetime in most people.
That stability changes the logic of the test. You are not monitoring a trend. You are learning a fact about your biology once and then building on it for decades. It also means a single elevated result is never a mistake to recheck away. It is a finding to integrate.
Who should be tested and when
The case for checking once in adulthood applies to nearly everyone and it becomes urgent for specific groups:
- Anyone with a family history of heart attack or stroke before about 55 in a male relative or 65 in a female relative.
- Anyone with a personal history of premature cardiovascular disease or unexplained disease at any age with unremarkable standard labs.
- People with familial hypercholesterolemia or very high LDL that does not respond to lifestyle as expected.
- Perimenopausal women, because Lp(a) rises transiently with estrogen changes and the post-menopausal years are when its cardiovascular weight grows.
- Anyone planning a family, because the trait is inherited in a dominant pattern and siblings and children deserve the same knowledge.
How Lp(a) values are read
| Result (mg/dL) | Interpretation | What it changes |
|---|---|---|
| Under 30 | Low | No special action, standard risk management |
| 30 to 50 | Intermediate | Modest attention, consider earlier imaging discussions |
| Over 50 (about 125 nmol/L) | Elevated | Aggressive ApoB control, tighter blood pressure and glucose targets |
| Over 180 | Very high | Lifetime risk comparable to familial hypercholesterolemia, specialist-grade prevention |
What a high result actually changes
This is the part worth reading carefully, because the honest answer is not what most people expect. You cannot currently lower Lp(a) meaningfully. Lifestyle barely moves it. Statins do not lower it and can nudge it upward slightly. Niacin and PCSK9 inhibitors shave modest amounts without proof that the reduction improves outcomes. RNA-targeted therapies designed to cut Lp(a) substantially are in late-stage trials and if they succeed the calculus will change, but they are not available today.
What a high result changes is the intensity of everything else. Atherosclerosis is driven by the number of atherogenic particles, measured best by ApoB, acting over time on a vessel wall whose susceptibility Lp(a) partly sets. A person with elevated Lp(a) has less margin. Their target ApoB should be lower, their blood pressure controlled more tightly, their HbA1c watched earlier, their smoking cessation non-negotiable and their hs-CRP trend taken seriously. The 2022 AHA statement is explicit that management of elevated Lp(a) today means aggressive control of all modifiable risk factors.
That is also why we treat this as a system rather than a single number. In our practice Lp(a) never arrives alone. It arrives inside the quarterly Biomarker Audit beside ApoB, hs-CRP, HbA1c, insulin markers and the full hormone panel, because a risk factor that raises the stakes is only useful when the levers that respond to treatment are being measured with it. You can see how the full audit is structured in biomarker audits vs standard blood tests.
Why standard panels leave it out
No villain is required, only incentives. A standard lipid panel is cheap, automated and covered everywhere and it answers the question most office visits are built around. Lp(a) costs more per test and the result obligates a longer conversation about risk that the visit was not designed to hold. The result is a cardiovascular blind spot that has persisted for decades despite the genetics being settled science.
We included Lp(a) in the audit from the start because the question our members are asking is not whether their cholesterol panel is adequate for a physical exam form. It is whether any preventable cardiovascular risk is sitting in them unmeasured. That question has one honest answer and it requires the test.
What it costs, stated plainly
The Cardiometabolic Optimization Membership is one flat $299 per month for the clinical relationship. Your first charge is $598, one payment at checkout covering the first two months together, including the clinical intake and your first comprehensive Biomarker Audit with Lp(a), ApoB, hs-CRP, HbA1c, lipids, insulin markers and the full hormone and thyroid panels. From month three it is $299 per month, month to month and you can cancel anytime after the initial commitment.
Labs beyond the quarterly cadence are billed to you at pass-through cost with no markup. Prescriptions are billed separately by the pharmacy at pharmacy cost with zero markup, no molecule upcharge and no dose-escalation fee. One flat fee for the doctor. Zero markup on the medicine. We make money when you get healthier, not when your dose gets stronger. Clinical care is delivered by licensed physicians of Beluga Health, P.A., an independent Florida professional corporation licensed to practice in all 50 states, working under GoodLife Health's clinical protocols. All labs run through the Beluga Health lab network.
The objection we hear most
What is the point of a test with no treatment? The point is that prevention is not a single prescription. A high Lp(a) finding changes your ApoB target, your blood pressure urgency, your follow-up cadence and your family's screening decisions and it does so decades before any symptom. The claim that an untestable-and-untreatable number is useless only holds if you believe the only purpose of a lab is to select a drug. The purpose of a lab is to decide where attention pays off and Lp(a) is one of the sharpest examples in medicine.
If you want every modifiable risk measured and managed as one system, the eligibility assessment is the first step and Cardiometabolic Optimization: the definitive guide explains the full framework.
FAQ
What does the Lp(a) test measure?
It measures the concentration of lipoprotein(a), an LDL-like particle carrying a unique protein called apolipoprotein(a). It is determined almost entirely by genetics and it is an independent, causal risk factor for atherosclerotic disease and aortic stenosis.
Who should have Lp(a) checked?
Most modern guidance favors checking it at least once in every adult and earlier in anyone with a family history of early heart attacks or strokes, a personal history of premature cardiovascular disease or familial hypercholesterolemia.
Why is Lp(a) only measured once?
Because the value is set genetically and stays stable across a lifetime, changing little with diet or exercise. What changes is what you do about it, so the single measurement anchors a permanent risk profile rather than a routine.
What does a high Lp(a) result mean?
It means you carry an inherited risk factor that standard panels never surface. It also makes aggressive management of every modifiable risk, including ApoB, blood pressure, blood sugar and inflammation, more important rather than less, because the risks interact.
Can you lower Lp(a) itself?
Currently no approved therapy lowers Lp(a) meaningfully. Niacin and PCSK9 inhibitors produce modest reductions without proven outcome benefit and RNA-targeted therapies are in late-stage trials. Management today means controlling everything that multiplies with it.
How much does the Lp(a) test cost inside the membership?
Lp(a) is included in the quarterly Biomarker Audit, which is part of the $299 per month Cardiometabolic Optimization Membership. The first charge of $598 covers the first two months and additional labs beyond the quarterly cadence are billed at pass-through cost with no markup.
Is Lp(a) measured in children?
Family members including children can be tested, particularly in families with a strong history of early heart disease, since the trait is inherited in a dominant pattern. Testing in adulthood is the standard recommendation, with earlier testing reserved for high-risk families.
How is Lp(a) reported and what values matter?
Results are reported in mg/dL or nmol/L. Values below 30 mg/dL or under 50 nmol/L, are considered low, values above 50 mg/dL or 125 nmol/L indicate elevated risk and extremely high values above 180 mg/dL carry a lifetime risk comparable to familial hypercholesterolemia.
One last thing
If a parent or sibling had a heart attack early, ask your family what was measured and what was not. Then ask yourself whether you want the one number nobody has ever drawn. It is a single blood draw, it is answered once and it reframes the next forty years of prevention decisions. That trade favors almost anyone.
Related guides
- ApoB test: what the number means for heart risk
- Biomarker audits vs standard blood tests
- Cardiometabolic optimization: the definitive guide
References
- Lipoprotein(a): A Genetically Determined, Causal, Common Risk Factor for Atherosclerotic Cardiovascular Disease (AHA Scientific Statement). 2022. doi.org/10.1161/CIR.0000000000000966
- European Atherosclerosis Society Consensus Statement on Lipoprotein(a) as a Causal Risk Factor. 2018. doi.org/10.1093/eurheartj/ehy162